Press releases

Non Regulatory

June 3, 2016

Oasmia Pharmaceutical announces early publication of Annual Report

Non Regulatory

April 29, 2016

Change in number of shares and voting rights in Oasmia Pharmaceutical AB (publ)

Non Regulatory

April 15, 2016

Oasmia successfully completes private placements of new convertible instruments and new shares in the total amount of SEK 45,5 million

Non Regulatory

March 10, 2016

Clarification regarding Press Release about Ovarian Cancer Market

Non Regulatory

March 10, 2016

Oasmia Pharmaceutical Seeks to Fill Void in Ovarian Cancer Treatment Market Indicated in Recent National Academy of Medicine Report

Non Regulatory

February 29, 2016

Oasmia Pharmaceutical Reissues Executive Summary

Non Regulatory

February 8, 2016

Oasmia Has Submitted a Marketing Authorization Application to the European Medicines Agency for Its Lead Cancer Product Apealea® (Paclical®)

Non Regulatory

February 4, 2016

Oasmia Pharmaceutical to Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference and BIO CEO & Investor Conference in New York

Non Regulatory

January 11, 2016

Oasmia Pharmaceutical AB (Nasdaq: OASM) to Ring the Nasdaq Stock Market Opening Bell on January 11

Non Regulatory

January 4, 2016

Oasmia Submits Application for Market Approval of its Next Generation Anti-Cancer Drug Doxophos® in Russia